Navigation Links
Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence
Date:9/24/2011

Stockholm, Sweden: A major UK trial has produced firm evidence that giving radiotherapy between or during chemotherapy cycles to women with early breast cancer significantly reduces the risk of the cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on the patients' quality of life.

Findings from the SEquencing of Chemotherapy and Radiotherapy in Adjuvant Breast cancer (SECRAB) study, which was carried out at 48 centres in the UK and is the largest study to investigate the treatment, will be presented today (Sunday) in Stockholm, to delegates at the 2011 European Multidisciplinary Cancer Congress [1].

"The results show that synchronous chemoradiation reduces the risk of local cancer recurrence by 35% in women with early breast cancer. After a follow-up of over eight years, only 41 patients in the synchronous chemoradiation group had suffered a recurrence compared with 63 patients in the sequential chemoradiation group," says Dr Indrajit Fernando, a Consultant Clinical Oncologist at University Hospitals Birmingham NHS Foundation Trust and Honorary Senior Lecturer at the University of Birmingham, UK.

Radiotherapy and chemotherapy are usually given after breast cancer surgery to destroy any remaining cancer cells in the breast, chest wall or underarm area, in order to reduce the risk of a local cancer recurrence. Sequential chemoradiation is the standard treatment schedule where chemotherapy is given first followed by radiotherapy.

Dr Fernando, the principal investigator of the study, will say: "The five-year local recurrence rates were 2.8% and 5.1% in the synchronous and sequential chemoradiation groups, respectively. This difference of 2.3% between treatment groups was statistically significant."

He will add: "According to the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), one breast cancer death can be avoided for every four local recurrences prevented [2]. Therefore, even a 2.3% reduction in local recurrence rates will have an impact worldwide when we consider that this is a very common cancer."

The optimal timing of radiotherapy with chemotherapy has been a subject of debate among cancer experts. The aim of this trial was to determine the best schedule for giving radiotherapy with cyclophosphamide/methotrexate/fluorouracil (CMF) or anthracyclineCMF chemotherapy after surgery to women with early breast cancer.

This randomised Phase III trial enrolled 2,296 women who had undergone breast conserving surgery (1,285 women) or mastectomy (1,011 women) to remove their tumour. All the patients received chemoradiation after surgery, either sequential (1,146 patients) or synchronous, where the radiotherapy was given in the gaps between chemotherapy cycles (1,150 patients). More than 60% of patients received 40Gy in 15 fractions over three weeks.

Dr Fernando also presents results from research into the quality of life of patients in the SECRAB study today. These focused on skin reactions caused by the radiotherapy, breast and arm symptoms and overall quality of life.

A total of 565 patients contributed to the quality of life analysis. Overall, the results showed that there were no observed differences in quality of life between the synchronous and sequential chemoradiation groups.

"Although the results of the main study showed that patients in the synchronous chemoradiation group had a significantly worse skin reaction, only four percent of patients in the synchronous arm had a severe reaction which would have taken several weeks to heal and subsequently affect quality of life. The majority of women had a moderate skin reaction which would have settled in a very short period of time and this had no detrimental effect on their quality of life," he says.

"Our data have shown that the acute skin toxicity of radiotherapy treatment was significantly less in patients being treated with three weeks of synchronous radiotherapy (40Gy radiation in 15 fractions) compared to those with schedules of a longer duration (45Gy in 20 fractions over four weeks or 50Gy in 25 fractions over five weeks). Importantly, the clinical benefit of synchronous chemoradiation treatment was seen in both patient groups."

Dr Fernando says that the trial could be important for economic reasons. "Shortening the overall treatment time may mean that when patients have finished their last chemotherapy course they can return to their normal life without having to then complete their radiotherapy. This may also have economic benefits in terms of when patients can return to work."

"Clinical practice needs to be reviewed for patients who are being treated with a CMF or an anthracycline/CMF chemotherapy schedule. The data will be forwarded to the National Institute of Clinical Excellence (NICE) in the UK but the results have implications worldwide," adds Dr Fernando.

Professor Michael Baumann, president of ECCO said: "This trial raises the important issue of how radiotherapy and chemotherapy after surgery should be sequenced or integrated to obtain the best outcome in breast cancer. In today's modern multidisciplinary oncology, not only each single component of treatment needs to be optimised, but also the combination thereof. This requires close interaction of specialists from different specialties in clinical research, as well as in everyday patient care. The SECRAB trial suggests that the risk of loco-regional recurrences could be reduced by applying radiotherapy simultaneously with chemotherapy. Long term follow-up will still be necessary to assess potential late side-effects and the benefits versus the risks of this approach, but I am convinced that this trial will spur a lot of discussion on optimising adjuvant treatment in this common disease."


'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
2. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
3. Radiotherapy can cause lasting vascular disease
4. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
5. Perioperative chemoradiotherapy in esophageal squamous cell carcinoma
6. Finding cancer cold spots can help minimize radiotherapy side-effects
7. Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. Stereotactic radiotherapy slows pancreatic cancer progression for inoperable patients
10. ASTRO publishes palliative radiotherapy for bone metastases guideline
11. BUSM study shows chemoradiotherapy prior to surgery improves survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Cifolelli has joined the company as Vice President of Sales. Cifolelli’s primary ... and international sales in the rapidly expanding field of organizational social engineering. ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, ... identity and website at its “Transforming Outcomes” User Conference in Las Vegas on ... i2i’s ongoing success to set the market standard for meaningful population health management. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... Georgia (PRWEB) , ... May 24, 2016 , ... Mental ... 1969 by the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is ... of its “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of ...
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... ... treatment for physical disease or injury that focuses on repairing the musculoskeletal and ... , With an emphasis on functional restoration, NYDNRehab began providing treatments for physical ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
Breaking Medicine Technology: